 |
|
Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis
A Randomized Controlled Trial
Thomas B. Casale, MD;
John Condemi, MD;
Craig LaForce, MD;
Anjuli Nayak, MD;
Michael Rowe, MD;
Marc Watrous, PhD;
Margaret McAlary, MS;
Angel Fowler-Taylor, RPh;
Amy Racine, PhD;
Niroo Gupta, MD,PhD;
Robert Fick, MD;
Giovanni Della Cioppa, MD;
for the Omalizumab Seasonal Allergic Rhinitis Trial Group
JAMA. 2001;286:2956-2967.
Context Seasonal allergic rhinitis is a common IgE-mediated disorder that produces troublesome symptoms. A recombinant humanized monoclonal anti-IgE antibody (omalizumab) forms complexes with free IgE, blocking its interaction with mast cells and basophils and lowering free IgE levels in the circulation.
Objective To assess the efficacy and safety of omalizumab for prophylaxis of symptoms in patients with seasonal allergic rhinitis.
Design Randomized, double-blind, dose-ranging, placebo-controlled trial conducted from July 25 through November 21, 1997.
Setting Twenty-five outpatient centers throughout the United States.
Patients Five hundred thirty-six patients aged 12 to 75 years with at least a 2-year history of moderate to severe ragweed-induced seasonal allergic rhinitis and a baseline IgE level between 30 and 700 IU/mL.
Interventions Patients were randomly assigned to receive omalizumab, 50 mg (n = 137), 150 mg (n = 134), or 300 mg (n = 129), or placebo (n = 136) subcutaneously just prior to ragweed season and repeated during the pollen season every 3 weeks in patients with baseline IgE levels of 151 to 700 IU/mL (4 total treatments) and every 4 weeks in patients with baseline IgE levels of 30 to 150 IU/mL (3 total treatments).
Main Outcome Measures Self-assessed daily nasal symptom severity scores (range, 0-3), rescue antihistamine use, and rhinitis-specific quality of life during the 12 weeks from the start of treatment.
Results Nasal symptom severity scores were significantly lower in patients who received 300 mg of omalizumab than in those who received placebo (least squares means, 0.75 vs 0.98, respectively; P = .002). A significant association was observed between IgE reduction and nasal symptoms and rescue antihistamine use. Rhinitis-specific quality of life scores were consistently better in patients who received 300 mg of omalizumab than in those who received lower dosages or placebo and did not decline during peak season. The frequency of adverse events was not significantly different among the omalizumab and placebo groups.
Conclusion Omalizumab decreased serum free IgE levels and provided clinical benefit in a dose-dependent fashion in patients with seasonal allergic rhinitis.
Author Affiliations: Department of Medicine, Creighton University, Omaha, Neb (Dr Casale); University of Rochester, Rochester, NY (Dr Condemi); North Carolina Clinical Research, Raleigh (Dr LaForce); Department of Pediatrics, University of Illinois at Chicago, Chicago (Dr Nayak); Michigan Respiratory Health and Research Institute, Novi (Dr Rowe); Genentech Inc, San Francisco, Calif (Drs Watrous and Fick); Novartis Pharmaceuticals Corp (Mss McAlary and Fowler-Taylor and Dr Gupta), East Hanover, NJ; Novartis Pharma AG, Basle, Switzerland (Dr Racine); and Novartis Horsham Research Centre, Horsham, England (Dr Della Cioppa).
RELATED ARTICLES
Immune-Based, Targeted Therapy for Allergic Diseases
Marshall Plaut
JAMA. 2001;286(23):3005-3006.
EXTRACT
| FULL TEXT
December 19, 2001
JAMA. 2001;286(23):3023-3024.
EXTRACT
| FULL TEXT
Seasonal Allergic Rhinitis
JAMA. 2001;286(23):3038.
PDF
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases
Bousquet et al.
ERR 2008;17:1-9.
ABSTRACT
| FULL TEXT
Omalizumab Reverses the Phenotypic and Functional Effects of IgE-Enhanced Fc{epsilon}RI on Human Skin Mast Cells
Gomez et al.
J. Immunol. 2007;179:1353-1361.
ABSTRACT
| FULL TEXT
Allergic rhinitis.
Plaut and Valentine
NEJM 2005;353:1934-1944.
FULL TEXT
Inflammatory Responses in Allergic Rhinitis: Traditional Approaches and Novel Treatment Strategies
Quraishi et al.
JAOA: Journal of the American Osteopathic Association 2004;104:7S-15S.
ABSTRACT
| FULL TEXT
Exhaled Nitric Oxide in Children With Asthma Receiving Xolair (Omalizumab), a Monoclonal Anti-Immunoglobulin E Antibody
Silkoff et al.
Pediatrics 2004;113:e308-e312.
ABSTRACT
| FULL TEXT
Evaluation of Impermeable Covers for Bedding in Patients with Allergic Rhinitis
Terreehorst et al.
NEJM 2003;349:237-246.
ABSTRACT
| FULL TEXT
OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02)
Evid. Based Nurs. 2003;6:e1-1.
FULL TEXT
Human Fc{varepsilon}RI{alpha}-Specific Human Single-Chain Fv (scFv) Antibody with Antagonistic Activity toward IgE/Fc{varepsilon}RI{alpha}-Binding
Hashiguchi et al.
J Biochem 2003;133:43-49.
ABSTRACT
| FULL TEXT
Is there a role for treatment of asthma with omalizumab?
Milgrom
Arch. Dis. Child. 2003;88:71-74.
ABSTRACT
| FULL TEXT
Immune-Based, Targeted Therapy for Allergic Diseases
Plaut
JAMA 2001;286:3005-3006.
FULL TEXT
|
